Roche and Ex­elix­is de­tail rare suc­cess for Cabome­tyx-Tecen­triq com­bo in prostate can­cer

The com­bi­na­tion of Roche’s check­point in­hibitor Tecen­triq and Ex­elix­is’ ki­nase in­hibitor Cabome­tyx staved off dis­ease pro­gres­sion of ad­vanced prostate can­cer for longer than a sec­ond hor­mone ther­a­py in a late-stage clin­i­cal tri­al.

The Phase III CON­TACT-02 study looked at metasta­t­ic prostate can­cer pa­tients who al­ready tried one hor­mone ther­a­py, and gave them ei­ther Roche and Ex­elix­is’ treat­ment or an­oth­er hor­mone ther­a­py. The com­bo can­cer reg­i­men ex­tend­ed me­di­an pro­gres­sion-free sur­vival by about two months com­pared to Zyti­ga or Xtan­di, ac­cord­ing to de­tailed da­ta shared at the AS­CO Gen­i­touri­nary Can­cers Sym­po­sium.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER